Purchase this article with an account.
Lauren C. Ditta, Asim F. Choudhri, Brian C. Tse, Mark M. Landers, Barrett G. Haik, Jena J. Steinle, J. Scott Williams, Matthew W. Wilson; Validating a Nonhuman Primate Model of Super-Selective Intraophthalmic Artery Chemotherapy: Comparing Ophthalmic Artery Diameters. Invest. Ophthalmol. Vis. Sci. 2012;53(12):7791-7794. doi: 10.1167/iovs.12-10605.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Superselective intraophthalmic artery chemotherapy (SSIOAC) is being used for treatment of retinoblastoma; however, the hemodynamic consequences and toxicities are not fully known. We developed a nonhuman primate (NHP) model of SSIOAC and reported our clinical observations. For validation, we compared ophthalmic artery (OA) diameters between NHPs and children (<6 years).
Endovascular cannulation of the right OA was performed three times each in six adult male Rhesus macaques. Angiographic OA images were obtained and measured, and postmortem OAs were histologically sectioned and measured. Retrospectively, computed tomography (CT) and magnetic resonance (MR) angiography images of the head in children and adolescents (as an adult reference) were used to measure the OA luminal diameter at its origin.
The median angiographic diameter of treated NHP OA origins (n = 6) was 1.06 mm (range 0.94–1.56). Histologic measurements (8 of 12 NHP OAs) gave a median diameter of 1.09 mm (range 0.95–1.41). In 98 children (from 169 consecutive CT and MR angiography studies; median age 1.01 years, range 0.01–5.74), 186 OAs were measurable at the origin (median luminal diameter 1.28 mm, range 0.82–2.00; P = 0.16 for the angiographic NHP diameters versus pediatric cohort). Angiographic measurements of 34 OAs (of 20 consecutive studies of adolescents; median age 16.55 years, range 14.40–18.18) gave a median luminal diameter of 1.45 mm (origin, range 1.13–1.66; P < 0.0001, adolescent versus pediatric).
Measurements of the OA luminal diameter at its origin were similar between our NHP and pediatric cohort, validating our NHP model for testing both the hemodynamic consequences and toxicities of SSIOAC.
This PDF is available to Subscribers Only